Molecules with therapeutic properties, including BRD4 and HDAC inhibitors, that reverse the action of mutant ASXL1 have been investigated, which suggests the potential treatment strategy against ASXL1-mutated leukemia [26,103,107]. The gene discussed is ASXL1; the disease is leukemia.